SenderraRx Teams Up With Nautic Partners for Future Growth and Innovation

SenderraRx Partners with Nautic Partners

In a strategic move to bolster its capabilities, SenderraRx, a leading specialty pharmacy dedicated to personalizing care for patients with complex conditions, has entered into a growth investment agreement with Nautic Partners. This partnership signals a robust commitment from both entities to enhance patient care and broaden access to essential therapies.

Founded in 2010 and based in Dallas, Texas, SenderraRx has gained recognition for its exceptional services, particularly in fields such as dermatology, rheumatology, and oncology. With a remarkable growth trajectory, the company was featured on the 2025 Inc. 5000 list for the second consecutive year, showcasing a staggering three-year revenue growth rate of over 60%.

The recent investment is poised to fuel further innovation within SenderraRx, highlighting its mission to provide high-quality patient outcomes across the United States. Will Howard, Co-Founder and CEO of SenderraRx, expressed excitement over the partnership, noting, "We are thrilled to partner with Nautic, whose proven experience in healthcare has the potential to supercharge our expanding access to life-changing therapies and elevate the patient experience."

A Patient-First Approach

The collaboration resonates with SenderraRx’s ethos of delivering compassionate and individualized care. With Nautic’s established track record in healthcare investments, SenderraRx is optimistic about enhancing its service offerings. “Together, we're poised to make an even greater impact in the lives of those we serve,” Howard added.

Keith Farrow, Managing Director at Nautic, emphasized that SenderraRx reflects the patient-centric approach essential for the future of specialty pharmacy. He noted, “We're excited to support Will and the team as they continue to innovate and grow, striving for exceptional outcomes in a rapidly evolving market.”

Expanding Collaborations and Outcomes

One of the key strengths of SenderraRx is its strong relationships with leading clinicians and pharmaceutical partners. Joe Anderson, Principal at Nautic, highlighted the firm’s admiration for these connections, anticipating deeper collaborations aimed at delivering excellent patient outcomes.

The financial advisory role was taken on by Cantor Fitzgerald, while legal advice for SenderraRx was provided by Bass, Berry & Sims. For Nautic, McDermott, Will & Emery served as legal counsel. The completion of this deal is anticipated in the first quarter of 2026, contingent upon the usual closing conditions.

About SenderraRx and Nautic Partners

SenderraRx dedicates itself to offering personalized support and healthcare solutions for patients navigating complex medical conditions. With a mission to ensure seamless access to medications and ongoing support, SenderraRx combines clinical expertise with advanced technologies.

On the other hand, Nautic Partners, LLC, based in Providence, Rhode Island, is a private equity firm focused on middle-market investments in healthcare, industrials, and services. With over 160 completed platform transactions in its nearly four-decade history, Nautic excels in nurturing its portfolio companies through strategic growth and deep sector expertise.

In summary, this partnership between SenderraRx and Nautic Partners embodies a significant leap forward in the specialty pharmacy arena, aiming to set new benchmarks in patient care and health outcomes for the years to come.